Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

A subtle ad about breast cancer self-checks led me to reflect on my own experience and the complex role of pharmaceutical companies in awareness.

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment ...

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive ...

Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural ...

Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of ...

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent ...